Fact is, revenues FELL sequentially, and that is awful for a growth stock. And, ceo neglected to explain it, but rather wrote up yoy. Look at fully diluted valuation -- dusa needs to grow quickly to justify it.
Easily manipulated stock because of the small number of shares outstanding and low pps. This enables anyone with just a few million USD to act out their dreams as a market manipulator and con the anxious and naive out of their shares either by running it up or running it down.
My advise is to just consider the fundamentals were are excellent (growth, cash position) and use this as an opportunity to acquire more shares.
sales up again but not as much as all would like.in a weak economy where other medical comp.sales are down 20-40% dusa held up very well. and building a great cash position. looks like 2million more shares added on. but .04 a share,twice better than expected.